← Oncology Approval Tracker

FDA DECISION ·

Gomekli

mirdametinib · SpringWorks Therapeutics

FDA approvalNew therapyNF1-associated plexiform neurofibromas
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children age 2 years or older with neurofibromatosis type 1 and symptomatic plexiform neurofibromas that cannot be fully removed surgically.

LAMPGEN ANALYSIS

Why it matters

This MEK inhibitor targets symptomatic benign nerve sheath tumors in both children and adults.

What research teams should watch

Plan baseline and follow-up imaging, ophthalmology, and cardiac assessments across pediatric and adult services.

PRIMARY RECORDS

Sources